News Gazyva is first FDA-cleared drug for rare disease pMN Patients in the US with primary membranous nephropathy have a first approved drug, after the FDA cleared Roche's Gazyva for the rare kidney disorder.
News Moderna shows in vivo CAR-T hand in R&D update At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News FDA kicks off review of Roche's Gazyva for wider lupus use Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.
News FDA knocks back AstraZeneca's self-injected lupus drug FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.
News NICE backs Roche lupus drug that supports kidney function Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.